How much does a box of Quizatinib cost?

Quizatinib is an oral small molecule receptor tyrosine kinase inhibitor specifically used to treat acute myeloid leukemia (AML) with FLT3-ITD mutation-positive acute myeloid leukemia (AML). FLT3-ITD mutation is a common genetic abnormality in AML and is closely related to disease recurrence and poor prognosis.

Quizatinib inhibits the activity of FLT3 kinase, blocks the autophosphorylation of FLT3 receptor, thereby inhibiting downstream signaling, effectively inhibiting FLT3-ITD-dependent cell proliferation, thereby slowing down the progression of AML. Clinical trials have shown that quizartinib can prolong the progression-free survival (PFS) and overall survival (OS) of AML patients, providing a new treatment option for AML patients, especially those with positive FLT3-ITD mutations.

Quizartinib is usually used in the form of oral tablets, and the recommended dosage and dosage regimen need to be individually adjusted based on the patient's specific condition and the guidance of the doctor. During the treatment process, patients may experience some adverse reactions, such as nausea, vomiting, diarrhea, fatigue, etc., but most adverse reactions are controllable, and doctors will take appropriate measures according to the patient's specific situation.

It is worth noting that quizartinib is not suitable for all AML patients. Its use needs to strictly follow the doctor's instructions and conduct FLT3 gene mutation testing before taking the drug to ensure that the patient is suitable for treatment with the drug. In addition, the use of quizartinib requires special caution in certain populations, such as patients with severe hypokalemia, severe hypomagnesemia, long QT syndrome, or a history of ventricular arrhythmias.

Quizatinib is not currently on the market in China, so it cannot be included in domestic medical insurance reimbursement items. It is understood that there are versions of Quizartinib marketed overseas. The original version marketed in Europe is 17.7mg*28 tablets and the price is about 80,000 yuan. The generic version marketed in Laos is 17.7mg*14 tablets and the price is about 1,800 yuan.

xa0

https://www.drugs.com/vanflyta.html